News & Press Releases
News & Press Releases
News & Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
Pursuant to this licensing agreement, PsyLabs will supply Psyence Biomed with pharmaceutical-grade, EU GMP nature-derived (non-synthetic) psilocybin to be evaluated in future clinical trials as a potential treatment for AUD and other SUDs, and for commercialization of the licensed product. Psyence Biomed plans to lead with a clinical trial in AUD, Psyence Biomed’s second development indication.
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New York.
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.
News and Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.